Good Start Genetics, Inc., a Cambridge MA-based molecular diagnostics company, closed a non-dilutive loan facility for up to $28m of capital from Capital Royalty L.P.
The company intends to use the funds to support its long-term corporate growth initiatives for its next-generation sequencing (NGS) based carrier screening platform.
Launched in April 2012 and led by Don Hardison, president and CEO, Good Start Genetics provides carrier screening for the in vitro fertilization (IVF) market, providing testing for all 23 diseases recommended by major medical societies and detects both common disease-causing mutations, as well as rare pathogenic mutations that would go undetected by laboratories using older genotyping-based technologies.
The company’s CLIA- and CAP-accredited laboratory has already processed tens of thousands of test orders.
FinSMEs
08/05/2013